BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30389467)

  • 1. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
    Busonero C; Leone S; Bartoloni S; Acconcia F
    Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
    Busonero C; Leone S; Bianchi F; Acconcia F
    Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
    Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
    J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
    Cipolletti M; Acconcia F
    Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    Acconcia F
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
    Busonero C; Leone S; Klemm C; Acconcia F
    Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
    Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
    Elife; 2022 May; 11():. PubMed ID: 35575456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
    Liang J; Ingalla ER; Yao X; Wang BE; Tai L; Giltnane J; Liang Y; Daemen A; Moore HM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Tam L; Bacarro N; Roose-Girma M; Bellet M; Hafner M; Metcalfe C
    Sci Transl Med; 2022 Sep; 14(663):eabo5959. PubMed ID: 36130016
    [No Abstract]   [Full Text] [Related]  

  • 13. A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.
    Cipolletti M; Bartoloni S; Busonero C; Parente M; Leone S; Acconcia F
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
    Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
    Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
    Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
    Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A functional genetic screen for metabolic proteins unveils GART and the
    Cipolletti M; Leone S; Bartoloni S; Acconcia F
    Front Endocrinol (Lausanne); 2023; 14():1129162. PubMed ID: 37143728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
    Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
    Elife; 2018 Nov; 7():. PubMed ID: 30489256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
    Merenbakh-Lamin K; Ben-Baruch N; Yeheskel A; Dvir A; Soussan-Gutman L; Jeselsohn R; Yelensky R; Brown M; Miller VA; Sarid D; Rizel S; Klein B; Rubinek T; Wolf I
    Cancer Res; 2013 Dec; 73(23):6856-64. PubMed ID: 24217577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
    Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
    Front Chem; 2019; 7():602. PubMed ID: 31552220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.